Moreover, in the AQP1 high expression group, PFS (P = 0.038) of breast cancer patients treated with CEF regimens was significantly longer than those treated with CMF regimens, and patients with the low AQP1 expression could not benefit from CEF regimens (Fig. 1g). Here, AQP1 is linked to breast carcinoma.